You searched for "surgical"

555 results found

Outcomes of renal cancer surgery on renal function and mortality on those with and without CKD

In urology we are encountering an ageing and more comorbid population, including a group of patients with chronic kidney disease (CKD). In this retrospective study, a group from the Cleveland Clinic present the extended follow-up of patients with and without...

Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomised controlled feasibility study

Prostate cancer is the commonest cancer and the second most frequent cause of cancer death in Western men [1]. The recent STAMPEDE data suggests a median survival of just 42.1 months in the control arm of metastatic men [2]. Current...

PSM increases risk of recurrence after PN for high-risk renal tumours

Positive surgical margins (PSM) for solid organ malignancies are associated with adverse oncological outcomes. However, for RCC the prognostic significance of PSM after partial nephrectomies (PN) remains a matter of debate. As PN is more increasingly being used to excise...

RN or PN for small RCCs – the debate continues

This is a retrospective study to evaluate kidney function and overall survival (OS) in patients who underwent partial nephrectomy (PN) and radical nephrectomy (RN) for RCCs <4cm. They looked at 2110 patients who underwent RN/PN for T1a renal cell carcinomas...

Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer

Abiraterone acetate, the prodrug of abiraterone, blocks endogenous androgen synthesis by inhibiting cytochrome p-450c17, a critical enzyme in androgen biosynthesis. Its active D4A metabolite also has anti-tumour effects through possibly multiple mechanisms. 3-5% of men diagnosed with prostate cancer in...

All biochemical recurrences are equal, but some are more equal than others

Despite significant technological advancements, radical prostatectomy (RP) and radiotherapy (RT) are not always effective in curing localised prostate cancer (PCa). Many patients experience a rise in prostate-specific antigen (PSA), known as biochemical recurrence (BCR), leading to considerable anxiety and a...

Trade-offs between risks and benefits of localised prostate cancer treatments – the COMPARE study

We know little about the trade-offs men make when considering the oncological and functional outcomes of individual treatment options for localised prostate cancer, and decisions are often influenced by physician opinion. The likely compromised functional results are viewed as a...

Stereotactic body radiotherapy for oligometastatic disease secondary to urological cancer

The concept of oligometastatic disease is controversial. The traditional model of cancer, which most of us learnt at medical school, is of a disease which starts confined to an organ, for example the prostate, where it can be cured with...

EMS Flexible Ureteroscopy and Percutaneous Surgery Masterclass

The Masterclass comprises a combination of didactic presentations, as-live surgery presentations, and live case observation on surgical techniques, tips and tricks, and the medical management of stone patients.

EMA Stone management with Endoscopic Combined Intrarenal Surgery (ECIRS)

The Masterclass comprises a combination of didactic presentations, as-live surgery presentations, and live case observation on surgical techniques, tips and tricks, and the medical management of stone patients.

EMS Stone management with Endoscopic Combined Intrarenal Surgery (ECIRS)

The Masterclass comprises a combination of didactic presentations, as-live surgery presentations, and live case observation on surgical techniques, tips and tricks, and the medical management of stone patients.

EMS Endoscopic Stone removal using Swiss LithoClast® Trilogy

The Masterclass comprises a combination of didactic presentations, as-live surgery presentations, and live case observation on surgical techniques, tips and tricks, and the medical management of stone patients.